Skip to content

Antiinflammatory therapy with canakinumab for atherosclerotic disease

One-paragraph summary

CANTOS randomized 10,061 prior-MI patients with hsCRP ≥2 mg/L to canakinumab at three doses or placebo. The 150-mg dose reduced recurrent cardiovascular events (HR 0.85) without changing LDL-C, while fatal infection increased and all-cause mortality was not reduced (Ridker 2017, PMID 28845751).

Key findings

  • IL-1β pathway inhibition can reduce atherosclerotic events independently of lipid lowering.
  • Inflammatory enrichment and biomarker response were integral to the design.
  • Safety and cost prevented routine cardiovascular adoption.

Limitations

  • Selected patients with persistent hsCRP elevation.
  • Dose multiplicity and hierarchical testing complicate broad claims.
  • Canakinumab-specific safety cannot be assigned to all anti-inflammatory drugs.

Why it matters

CANTOS transformed inflammation from association to a causal, druggable pathway while demonstrating that pathway success does not guarantee a viable clinical product.

Cited by wiki pages

  • Inflammation and residual risk
  • Pathophysiology
  • Biomarkers